Although the incidence of fatal pneumonitis associated with third-generation EGFR-TKIs has historically been regarded as low, real-world data on osimertinib indicate an overall fatal pneumonitis rate of approximately 1.1% (Sato et al., 2022). Here, EGFR is linked to pneumonitis.